Prostate International最新文献

{"title":"Prostate diseases and microbiome in the prostate, gut, and urine","authors":"Makito Miyake ,&nbsp;Yoshihiro Tatsumi ,&nbsp;Kenta Ohnishi ,&nbsp;Tomomi Fujii ,&nbsp;Yasushi Nakai ,&nbsp;Nobumichi Tanaka ,&nbsp;Kiyohide Fujimoto","doi":"10.1016/j.prnil.2022.03.004","DOIUrl":"10.1016/j.prnil.2022.03.004","url":null,"abstract":"<div><p>The microbiome in various organs involves a vast network that plays a key role in the health and wellness of the human body. With recent advances in biological technologies such as high-throughput sequencing, transcriptomics, and metabolomics, it appears that the microbial signature varies dynamically among individuals, creating various roles in metabolism, local and systemic inflammation, and host immunity. Urinary and genital organs, including the prostate, seminal vesicles, and urinary bladder, are reservoirs of several bacterial, viral, and fungal communities. Accumulating evidence has suggested profound roles for the gut, urinary, and intraprostate microbiomes in genitourinary benign and malignant diseases. This review article addresses microbiome-related evidence for three major diseases involved in prostate cancer: chronic prostatitis (CP), benign prostatic hyperplasia (BPH), and prostate cancer (PCa). Symptomatic CP is known as CP/chronic pelvic pain syndrome. CP is one of the most common prostate diseases in young men, accounting for 8% of all men visiting a urologic clinic. Although oral medication is the gold standard therapy for patients with BPH, approximately 13% of men present with clinical progression within 4 years after the initiation of treatment, with 5% requiring surgical intervention. The identification of proinflammatory cytokines and pathogens responsible for the clinical progression of BPH is still underway. Several topics regarding the association between PCa and the microbiome are discussed in this review as follows: i) intraprostatic microbiome and the risk of PCa, ii) gut microbiome and PCa, iii) gut microbiome and the risk of radiation-induced side effects, iv) isoflavone intake and equol-producing intestinal flora on PCa, and v) the inhibitory effect of daidzein and equol on tumor growth and progression of PCa. Further studies are required for a comprehensive understanding between the urogenital microbiome and prostate pathogenesis to facilitate the development of preventive and therapeutic approaches for prostate diseases.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000174/pdfft?md5=428e4d0fd6434515df8f9948d6c641b0&pid=1-s2.0-S2287888222000174-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45334601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score–matched analysis","authors":"Jun Ho Lee ,&nbsp;Yeon Won Park ,&nbsp;Sin Woo Lee ,&nbsp;Jae Duck Choi ,&nbsp;Jung Yoon Kang ,&nbsp;Tag Keun Yoo","doi":"10.1016/j.prnil.2022.03.002","DOIUrl":"10.1016/j.prnil.2022.03.002","url":null,"abstract":"<div><h3>Background</h3><p>We investigated the association between moderate-to-severe prostatitis-like symptoms and the predictors of benign prostatic hyperplasia (BPH) progression.</p></div><div><h3>Methods</h3><p>Men who underwent health checkups were analyzed. We classified symptoms as “moderate to severe” if the pain score according to the National Institutes of Health-Chronic Prostatitis Symptoms Index was ≥8 and predictors of the progression of BPH were defined as having a prostate-specific antigen (PSA) ≥1.6 ng/mL, total prostate volume (TPV) ≥31 mL, international prostate symptom score (IPSS) ≥20, and maximal flow rate (Q_max) &lt;10.6 mL/s. A total of 8368 patients formed the cohort for propensity score matching, including 445 men with moderate-to-severe prostatitis-like symptoms and 5390 men with no symptoms; ultimately, however, the propensity score of these groups matched at a 1:2 ratio.</p></div><div><h3>Results</h3><p>After propensity matching, the two groups were evenly distributed with respect to age, International Index of Erectile Function-5 score, metabolic syndrome, and testosterone. The percentage of participants with ≥1 predictor for the progression of BPH, a TPV of ≥31 cm³, PSA levels of ≥1.6 ng/mL, Q_max &lt;10.6 mL/s, and IPSS ≥20 were all greater in men with moderate-to-severe prostatitis-like symptoms. There were significant differences in the percentage of participants with ≥1 predictor for the progression of BPH (30.6% vs. 58.0%; p &lt; 0.001), Q_max &lt;10.6 mL/s (3.9% vs. 7.0%, p = 0.023), and IPSS ≥20 (9.6% vs. 44.7%, p &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Moderate-to-severe prostatitis-like symptoms are significantly and independently associated with predictors of BPH progression.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000150/pdfft?md5=0d9f6582266fd46e4cbb8d0b84f29d1d&pid=1-s2.0-S2287888222000150-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48450970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial experience of single-port robot-assisted radical prostatectomy: A single surgeon's experience with technique description","authors":"Tae Il Noh,&nbsp;Jong Hyun Tae,&nbsp;Ji Sung Shim,&nbsp;Seok Ho Kang,&nbsp;Jun Cheon,&nbsp;Jeong Gu Lee,&nbsp;Sung Gu Kang","doi":"10.1016/j.prnil.2021.10.003","DOIUrl":"10.1016/j.prnil.2021.10.003","url":null,"abstract":"<div><h3>Background</h3><p>With the implementation of da Vinci SP robot platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA), we described our initial experience with the da Vinci SP robot platform (Intuitive Surgical, Inc., Sunnyvale, CA, USA) for single-port robotic-assisted radical prostatectomy (SP-RARP).</p></div><div><h3>Methods</h3><p>This retrospective review included 30 consecutive patients with prostate biopsy-confirmed prostate cancer who underwent SP-RARP by a single surgeon between June and November 2020. SP-RARP was performed with a single-incision plus one method, in which the multichannel guide port was inserted directly with an additional assist port. We report our initial experience of perioperative and early functional outcomes.</p></div><div><h3>Results</h3><p>The mean operative time (SD), console time (SD), and blood loss were 142.8 (15.1) min, 109.9 (15.7) min, and 133.0 (72.9) mL, respectively. No intraoperative complications or blood transfusions were reported. Of the 30 patients, 21 (70.0%), 7 (23.3%) and 2 (6.7%) had stage pT2, pT3a and pT3b disease, respectively. Positive surgical margins were reported in 5 of the 30 (16.7%) patients in the final pathology report, including 2 of 21 (9.5%) with stage pT2 and 3 of 9 (33.3%) with ≥ pT3. At 12 weeks after SP-RARP, 80.0% of patients had achieved continence and the potency was 46.7%; 8 of 11 (72.7%) had sexual health inventory for men (SHIM) scores ≥ 17 and 6 of 19 (31.6%) had SHIM scores &lt; 17.</p></div><div><h3>Conclusions</h3><p>The SP platform for radical prostatectomy was technically safe and feasible. After overcoming the technical learning curve, this platform may provide high-quality outcomes comparable to those of multi-port platforms.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888221000581/pdfft?md5=d611436f8e9ec72b70346ba5278bb2eb&pid=1-s2.0-S2287888221000581-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44690214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer","authors":"Yuping Zeng ,&nbsp;Xiaoming Leng ,&nbsp;Hengbin Liao ,&nbsp;Guihua Jiang ,&nbsp;Ping Chen","doi":"10.1016/j.prnil.2022.03.003","DOIUrl":"10.1016/j.prnil.2022.03.003","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the diagnostic value of fluorine 18 (¹⁸F)-labeled prostate-specific membrane antigen (PSMA)-1007 Positron emission tomography/Magnetic resonance imaging (PET/MRI) and compared with that of biparametric MRI (bpMRI) for the detection of prostate cancer (PCa).</p></div><div><h3>Materials and methods</h3><p>The study enrolled 29 patients with suspected PCa preoperatively who underwent ¹⁸F-PSMA-1007 PET/MRI and subsequent targeted biopsy for suspected PCa lesions. Two readers independently assessed the images of each suspected PCa lesion and determined their overall assessment category on bpMRI and ¹⁸F-PSMA-1007 PET/MRI. By using biopsy histopathology as the reference standard, the accuracies of ¹⁸F-PSMA-1007 PET/MRI and bpMRI for the detection of PCa lesion were determined. Furthermore, the receiver-operating characteristic (ROC) curves of their semi-quantitative parameters of the optimal standardized uptake value (SUVmax) and apparent diffusion coefficient (ADC) for detecting PCa lesions were derived, and their correlations with the International Society of Urological Pathology (ISUP) grade were reported.</p></div><div><h3>Results</h3><p>Of the 48 suspected PCa lesions in 29 patients, 38 were pathologically diagnosed with clinically significant PCa and 10 with nonprostate cancer (non-PCa) lesions. Compared with the pathological results, ¹⁸F-PSMA-1007 PET/MRI demonstrated much greater diagnostic accuracy (area under the curve, AUC), sensitivity, specificity, positive predictive value, and negative predictive value than bpMRI: 0.974 versus 0.711, 94.74% versus 92.11%, 100% versus 50%, 100% versus 87.50%, and 83.33% versus 62.50%, respectively. The semi-quantitative parameters of SUVmax demonstrated a higher AUC of 0.874 than that of ADC with 0.776 for detecting PCa. The ISUP grade was positively associated with SUVmax at spearman’s rho correlation coefficient (Rho) = 0.539, p = 0), but not associated with ADC (Rho = −0.105, p = 0.529).</p></div><div><h3>Conclusion</h3><p>The diagnostic value of ¹⁸F-PSMA-1007 PET/MRI for the detection of PCa is better than that of bpMRI, and a high SUVmax may indicate a lesion with a high ISUP grade.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000162/pdfft?md5=0c3988dded48189e5135f16ea1f6c926&pid=1-s2.0-S2287888222000162-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44788711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis on the use of radiotherapy after prostatectomy: adjuvant versus early salvage radiation","authors":"Joseph F. Renzulli II ,&nbsp;Joseph Brito III ,&nbsp;Isaac Y. Kim ,&nbsp;Isabella Broccoli","doi":"10.1016/j.prnil.2022.01.003","DOIUrl":"10.1016/j.prnil.2022.01.003","url":null,"abstract":"<div><p>To determine which method of radiotherapy proves more effective after prostatectomy: Adjuvant (ART) or early salvage (ESRT), we observed the pathologic and adverse risk factors of patients and their results from both treatments, looking specifically at biochemical-free survival rates, metastasis-free survival rates, and overall survival rates. Peer review articles containing their own data collected between 1986 and 2022 were reviewed. We reviewed 67 peer review articles and included 33 that met criteria. Studies focused on the adverse risk factors and the results of patients either before/after receiving adjuvant or early salvage/salvage radiotherapy were included in the analysis. Patient characteristics had an effect on what treatment a patient would receive; if a patient had more than one adverse risk factor such as a high Gleason score, prostate-specific antigen (PSA) level, T-stage, or positive margins, they would receive immediate radiation after prostatectomy, which would classify as ART. If the patient had no adverse risk factors after surgery, they would be placed in an observation period to follow their PSA and overall health, and only if necessary, undergo ESRT. Of the 33 studies, ART was proven to be only slightly more beneficial when relating to biochemical recurrence-free survival while ART and ESRT results were similar in metastasis-free survival and overall survival. ART and ESRT are overall comparable in their patient outcomes, despite their own unique pros and cons. The use of ESRT reduces overtreatment in men who may not experience biochemical recurrence. However, in those with very high-risk pathologic features, a multi-disciplinary approach should be utilized to best determine which mode of radiation therapy after surgery is recommended.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/bf/main.PMC9043851.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9166464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy","authors":"Isaac Yi Kim ,&nbsp;Antonina Mitrofanova ,&nbsp;Sukanya Panja ,&nbsp;Joshua Sterling ,&nbsp;Arnav Srivastava ,&nbsp;Juliana Kim ,&nbsp;Sinae Kim ,&nbsp;Eric A. Singer ,&nbsp;Thomas L. Jang ,&nbsp;Saum Ghodoussipour ,&nbsp;Biren Saraiya ,&nbsp;Tina Mayer ,&nbsp;Hatem E. Sabaawy ,&nbsp;Bertram Yuh ,&nbsp;Seok Soo Byun ,&nbsp;Wun-Jae Kim ,&nbsp;Shigeo Horie","doi":"10.1016/j.prnil.2022.03.001","DOIUrl":"10.1016/j.prnil.2022.03.001","url":null,"abstract":"<div><h3>Purpose</h3><p>Approximately 7% of patients with newly diagnosed prostate cancer (PCa) in the US will have have metastatic disease. The dogma that there is no role for surgery in this population has been questioned recently. Here we report long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy.</p></div><div><h3>Materials and methods</h3><p>This is a multicenter phase 1 trial. The major inclusion criterion was biopsy proven N1M0 or NxM1a/b PCa. Primary end point was the Clavien-Dindo-based major complication rate. Secondary outcomes were biochemical progression and overall survival. RNA-seq correlative study was conducted in nine select cases as a pilot study.</p></div><div><h3>Results</h3><p>Final accrual was 32 patients of which 25 and 7 were cNxM1 and cN1M0, respectively. With the median follow-up of 46 months (interquartile range 31.7 - 52.7 months), 25 out of the 32 patients (75%) were alive at the time of last contact. There were three disparate groups based on the oncologic outcome: favorable, intermediate, and poor. In seven men with favorable response, androgen deprivation therapy was switched to intermittent approach and five remain free of any evidence of disease after more than two years off all systemic therapy with the normalization of serum testosterone. Of these five patients, three had M1 disease. Long-term use of one pad or less per day was 80%. RNA-seq analysis revealed an enriched downregulation of tumor necrosis factor (TNF)-α signature in the favorable group.</p></div><div><h3>Conclusion</h3><p>Overall long-term oncologic outcome of cytoreductive radical prostatectomy was significantly higher than historical results. Importantly, the combination of surgery with systemic therapy may result in a long durable response in a minority of men who present with metastatic PCa.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/bd/main.PMC9035380.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10393151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer","authors":"Hyungseok Cho ,&nbsp;Cheol Kyu Oh ,&nbsp;Jiwon Cha ,&nbsp;Jae Il Chung ,&nbsp;Seok-Soo Byun ,&nbsp;Sung Kyu Hong ,&nbsp;Jae-Seung Chung ,&nbsp;Ki-Ho Han","doi":"10.1016/j.prnil.2022.01.002","DOIUrl":"10.1016/j.prnil.2022.01.002","url":null,"abstract":"<div><h3>Background</h3><p>Prostate-specific antigen (PSA) is used for diagnosing prostate cancer, but does not reflect the characteristics of prostate cancer cells to allow assessment of cancer progression. PSA mRNA and circulating tumor cells (CTCs) could be potential biomarkers. However, the relationship between serum PSA levels and PSA mRNA in CTCs is unclear, and this study aimed to investigate this relationship.</p></div><div><h3>Methods</h3><p>Healthy donors (HD, <em>n</em> = 9), and patients with local non-metastatic stage prostate cancer (<em>n</em> = 30), metastatic hormone–sensitive prostate cancer (mHSPC, <em>n</em> = 10), and metastatic castration–resistant prostate cancer (mCRPC, <em>n</em> = 75), were included. The expression of PSA mRNA in CTCs was measured by droplet digital PCR. Serum PSA (ng/mL) levels and PSA mRNA (copies/μL) in CTCs were then compared using Spearman correlation coefficients.</p></div><div><h3>Results</h3><p>PSA mRNA expression in CTCs was observed in 30% (9/30) of patients with localized cancer, 60.0% (6/10) among patients with mHSPC, 65.3% (49/75) among patients with mCRPC, and 0% among patients with HD, indicating that the detection rate of PSA mRNA increased with cancer stage. PSA mRNA expression in CTCs also increased from localized to metastatic stages. PSA mRNA levels rapidly increased in the mHSPC and mCRPC stages. Interestingly, PSA mRNA expression in CTCs was not correlated with serum PSA levels at the localized stage (<em>R</em> = 0.064, <em>P</em> = 0.512). However, there were significant correlations between serum PSA levels and PSA mRNA expression in mHSPC (<em>R</em> = 0.532, <em>P</em> = 0.041) and mCRPC (<em>R</em> = 0.566, <em>P</em> = 0.025). The number of CTCs isolated from mHSPC and mCRPC was not proportional to serum PSA and PSA mRNA levels.</p></div><div><h3>Conclusion</h3><p>CTC PSA mRNA has the potential to be used as a biomarker to complement serum PSA protein analysis or replace serum PSA in metastatic stages of prostate cancer.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000022/pdfft?md5=aef2bbac196fdd52475525bfcecdc5f2&pid=1-s2.0-S2287888222000022-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46373913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer","authors":"Benedikt Hoeh ,&nbsp;Rocco Flammia ,&nbsp;Lukas Hohenhorst ,&nbsp;Gabriele Sorce ,&nbsp;Francesco Chierigo ,&nbsp;Zhe Tian ,&nbsp;Fred Saad ,&nbsp;Michele Gallucci ,&nbsp;Alberto Briganti ,&nbsp;Carlo Terrone ,&nbsp;Shahrokh F. Shariat ,&nbsp;Markus Graefen ,&nbsp;Derya Tilki ,&nbsp;Luis A. Kluth ,&nbsp;Philipp Mandel ,&nbsp;Felix K.H. Chun ,&nbsp;Pierre I. Karakiewicz","doi":"10.1016/j.prnil.2022.01.004","DOIUrl":"10.1016/j.prnil.2022.01.004","url":null,"abstract":"<div><h3>Background</h3><p>Up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown.</p></div><div><h3>Methods</h3><p>We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (≤ cT2c and PSA ≤ 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010–2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading.</p></div><div><h3>Results</h3><p>Of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; <em>p</em> = 0.3), median age (62 vs 63 years; <em>p</em> = 0.07) and cT1-stage (77 vs 75%; <em>p</em> = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10–20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR:2.89; 95%-CI: 1.31–6.11; <em>p</em> = 0.007).</p></div><div><h3>Conclusion</h3><p>In single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888222000046/pdfft?md5=33cb0c21406855f3f129320f56e3a70a&pid=1-s2.0-S2287888222000046-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46027317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is antibiotic prophylaxis still mandatory for transperineal prostate biopsy? Results of a comparative study","authors":"Giacomo M. Pirola ,&nbsp;Marilena Gubbiotti ,&nbsp;Emanuele Rubilotta ,&nbsp;Daniele Castellani ,&nbsp;Nicolò Trabacchin ,&nbsp;Alessandro Tafuri ,&nbsp;Alessandro Princiotta ,&nbsp;Eugenio Martorana ,&nbsp;Filippo Annino ,&nbsp;Alessandro Antonelli","doi":"10.1016/j.prnil.2021.11.001","DOIUrl":"10.1016/j.prnil.2021.11.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>This study aimed to assess the incidence of urinary tract infections (UTIs) after transperineal prostate biopsy (TP-PB) comparing patients who underwent antibiotic prophylaxis (AP) with patients who had no prophylaxis.</p></div><div><h3>Materials and methods</h3><p>This prospective, double-center trial was conducted between August and December 2020. Patient candidates to PB were included with 1:1 allocation to case (Group A-no AP) and control group (Group B-standard AP). All TP-PBs were performed in an outpatient setting under local anesthesia. Data collected 2 weeks after the procedure included incidence of UTIs or bacteriuria, evaluated with a urine culture (UC), main symptoms, and complications related to TP-PBs.</p></div><div><h3>Results</h3><p>A total of 200 patients were included (100 patients in each group). The mean age was 66.2 ± 7.7 in Group A and 67.4 ± 8 years in Group B (<em>P</em> = 0.134). Mean prostate volume was 65.5 ± 26.7 vs. 51 ± 24.6 cc (<em>P</em> &lt; 0.001), number of biopsy cores was 17.8 ± 2.4 vs. 14.9 ± 0.8 (<em>P</em> &lt; 0.001), and PSA value was 15.9 ± 28.1 vs. 13.3 ± 22.3 ng/ml (<em>P</em> = 0.017). Overall PCa detection rate was 55% vs. 59% (<em>P</em> = 0.567). Postoperative UTI occurred in one patient in Group A vs. zero in Group B. Asymptomatic bacteriuria was present in 3 vs. 5 patients (<em>P</em> = 0.470) and was not treated with antibiotics. Postoperative hematuria was observed in 13 patients vs. 29 (<em>P</em> &lt; 0.05), and acute urinary retention was observed in one patient in each group.</p></div><div><h3>Conclusions</h3><p>The incidence of bacteriuria and UTIs in TP-PBs is not related to AP. Therefore, AP could be discontinued in TP-PB candidates without the risk of increasing UTI-related complications.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2287888221000593/pdfft?md5=a5734c2ff34da98fb9a3de7084451500&pid=1-s2.0-S2287888221000593-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47152041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?","authors":"Myungsun Shim,&nbsp;Woo Jin Bang,&nbsp;Cheol Young Oh,&nbsp;Yong Seong Lee,&nbsp;Jin Seon Cho","doi":"10.1016/j.prnil.2021.02.002","DOIUrl":"10.1016/j.prnil.2021.02.002","url":null,"abstract":"<div><p>The expansion of the indication to use androgen deprivation therapy (ADT) to treat patients with advanced or metastatic prostate cancer has dramatically increased over the recent decades, resulting in the progress of patients’ survival. However, chronic health implications can become more apparent as the number of long-term cancer survivors is expected to be increased along with the adverse effect of ADT. In particular, interest in investigating ADT, especially luteinizing hormone-releasing hormone (LHRH) agonist association with cognitive dysfunction has been growing. Previous studies in animals and humans suggest that the level of androgen decreases with age and that cognitive decline occurs with decreases in androgen. Correspondingly, some of the extensive studies using common neurocognitive tests have shown that LHRH agonists may affect specific domains of cognitive function (e.g., visuospatial abilities and executive function). However, the results from these studies have not consistently demonstrated the association because of its intrinsic limitations. Large-scale studies based on electronic databases have also failed to show consistent results to make decisive conclusions because of its heterogeneity, complexity of covariates, and possible risk of biases. Thus, this review article summarizes key findings and discusses the results of several studies investigating the ADT association with cognitive dysfunction and risk of dementia from various perspectives.</p></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.prnil.2021.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48184020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}